Risk stratification and treatment benefits in patients with non-ST-elevation acute coronary syndromes

European Heart Journal

Volumn 23, Issue 3, 2002, Pages 187-191

  White, H D ^a   Wong, C K ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MACROGOL; TIROFIBAN; TROPONIN I; TROPONIN T; VON WILLEBRAND FACTOR;

BLOOD LEVEL; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART RATE; HEART VENTRICLE FUNCTION; HIGH RISK POPULATION; HUMAN; MORTALITY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; ST SEGMENT ELEVATION; SURVIVAL RATE; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; BIOLOGICAL MARKERS; CORONARY DISEASE; CREATINE KINASE; CREATINE KINASE, MB FORM; ELECTROCARDIOGRAPHY; HUMANS; ISOENZYMES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK ASSESSMENT; SYNDROME; TREATMENT OUTCOME; TROPONIN; VENTRICULAR FUNCTION, LEFT;

EID: 0036488069     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2904     Document Type: Editorial

References (41)

1. Boersma E, Pieper KS, Steyerberg EW et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation 2000; 101: 2557-67.
2. Cannon CP, Thompson B, McCabe CH et al. Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III Trials. Am J Cardiol 1995; 75: 977-81.
3. Hyde TA, French JK, Wong C-K, Straznicky IT, Whitlock RML, White HD. Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression. Am J Cardiol 1999; 84: 379-85.
4. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIB Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
5. Antman EM, Cohen M, Bernink PJ et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-42.
6. Hamm CW, Ravkilde J, Gerhardt W et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327: 146-50.
7. Lindahl B, Andrén B, Ohlsson J, Venge P, Wallentin L, and the FRISK Study Group. Risk stratification in unstable coronary artery disease: additive value of troponin T determinations and pre-discharge exercise tests. Eur Heart J 1997; 18: 762-70.
8. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol 1997; 29: 43-8.
9. Heeschen C, Hamm CW, Goldmann B et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999; 354: 1757-62.
10. Bahit MC, Shah M, Granger C et al. Prognostic significance of manifestations of acute congestive heart failure: results from GUSTO IIb [abstract]. J Am Coll Cardiol 2000; 35 (Suppl A): 213A.
11. McGuire DK, Emanuelsson H, Granger CB et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes: findings from the GUSTO-IIb Study. Eur Heart J 2000; 21: 1750-8.
12. Zhao X-Q, Théroux P, Snapinn SM, Sax FL, for the PRISM-PLUS Investigators. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: angiographic results from the PRISM-PLUS Trial (Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms). Circulation 1999; 100: 1609-15.
13. Antman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/ non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) IIB Trial. Circulation 1999; 100: 1593-601.
14. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-52.
15. Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes: application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002; 23: 223-9, doi:10.1053/euhj.2001.2738.
16. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
17. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349-60.
18. Waters D, Lam JYT, Is thrombolytic therapy striking out in unstable angina? Circulation 1992; 86: 1642-4.
19. Bertrand ME, Simoons ML, Fox KAA et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406-32.
20. Ottani F, Galvani M, Nicolini FA et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000; 140: 917-27.
21. Heeschen C, van den Brand MJ, Hamm CW, Simoons ML, for the CAPTURE Investigators, Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 1999; 104: 1509-14.
22. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-8.
23. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
24. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-Plus) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
25. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
26. Kong DF, Califf RM, Miller DP et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829-35.
27. Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronaryartery disease: FRISC II Prospective Randomised Multicentre Study. Lancet 1999; 354: 708-15.
28. Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-87.
29. Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease (FRISC II) Investigators. Longterm low-molecular-mass heparin in unstable coronary-artery disease: FRISC II Prospective Randomised Multicentre Study [published erratum appears in Lancet 1999; 354: 1478]. Lancet 1999; 354: 701-7.
30. Gum PA, Kottke-Marchant K, Poggio ED et al. Profile and prevalence of aspirin resistance among patients with heart disease: a prospective, comprehensive assessment [abstract]. Circulation 2000; 102 (Suppl II): II-418.
31. Yamagishi S-I, Edelstein D, Du X-L, Brownlee M. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes 2001; 50: 1491-4.
32. The EPISTENT Investigators. Randomised placebocontrolled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
33. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000; 36: 970-1062.
34. The American Heart Association in Collaboration with the International Liaison Committee on Resuscitation (ILCOR). Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care: an international consensus on science, Part 7: The era of reperfusion. Section 1: Acute coronary syndromes (acute myocardial infarction). Circulation 2000; 102 (Suppl I): I-172-I-203.
35. Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes. Technology Appraisal Guidance No. 12. National Institute for Clinical Excellence, London, England, September 2000.
36. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ, Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44-51.
37. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000; 35: 1535-42.
38. Montalescot G, Philippe F, Ankri A et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Circulation 1998; 98: 294-9.
39. Montalescot G, Collet JP, Lison L et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36: 110-4.
40. Ohman EM, Granger CB, Harrington RA, Lee KL. Risk stratification and therapeutic decision making in acute coronary syndromes [commentary]. JAMA 2000; 284: 876-8.
41. Newby LK, Storrow AB, Gibler WB et al. Bedside multimarker testing for risk stratification in chest pain units: the Chest Pain Evaluation by Creatine Kinase-MB, Myoglobin, and Troponin I (CHECKMATE) Study. Circulation 2001; 103: 1832-7.